MGBBP-3 is under clinical development by MGB Biopharma and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect MGBBP-3’s likelihood of approval (LoA) and phase transition for Clostridioides difficile Infections (Clostridium difficile Associated Disease) took place on 02 Dec 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their MGBBP-3 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

MGBBP-3 overview

MGBBP-3 is under development for the treatment of Clostridium difficile infections, gram-positive bacteria which includes methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-resistant Enterococci (VRE), Streptococcal infections, Staphylococcus aureus (HA-MRSA) infections. The drug candidate is administered through oral route as a capsule and tablet, intravenous route as a solution and topical route as a cream. It is an anti-bacterial minor groove binder (AbMGB) agent that acts by targeting DNA. The drug candidate is developed based on DNA minor groove binder (MGB) technology. It was also under development for Enterococcus infections, Neisseria meningitides and Moraxella catarrhalis.

MGB Biopharma overview

MGB Biopharma is a a biopharmaceutical company which develops novel class of anti-infectives using Minor Groove Binder (MGBs) compounds. Its lead drug candidate MGB-BP-3 in the field of antibacterial resistance is active against may Gram-positive bacteria. MGB Biopharma also developed an oral formulation of MGB-BP-3 for Clostridium difficile. The company’s technology platform provides an opportunity to develop various compounds against multi-resistant Gram-negative pathogens, fungi, viruses, and parasitic diseases. It works in partnership with the University of Strathclyde, and other pharmaceutical companies for the advancement of its novel anti-infectives platform. MGB Biopharma is headquartered in Bellshill, Scotland, the UK.

Quick View MGBBP-3 LOA Data

Report Segments
  • Innovator
Drug Name
  • MGBBP-3
Administration Pathway
  • Intravenous
  • Oral
  • Topical
Therapeutic Areas
  • Infectious Disease
Key Developers
  • Sponsor Company: MGB Biopharma
  • Originator: University of Strathclyde
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.